Company intelligence / Profile preview
TG ImmunoPharma Co., Ltd.
Hefei, Anhui Sheng / Anhui Province, Chinatgimmunopharma.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
TG ImmunoPharma has received FDA clearance for multiple IND applications. Its lead programs include TGI‑2/NM1F (anti-PVRIG monoclonal antibody) and TGI‑6 (bispecific antibody), both of which have entered Phase 1 clinical trials targeting advanced solid tumors. Preclinical data show strong anti-tumor activity with good safety profiles. The company has over ten pipeline products with more than half having completed preclinical studies. Three innovative drugs are expected to enter Phase I trials by end of next year.
- Therapeutic areas
- OncologyEndocrinologyImmunologyGastroenterologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodiesCytokinesImmune checkpoint inhibitorsNK/T-cell engagersImmunocytokines
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Actively seeking global partners for development/commercialization of its lead assets; no major partnerships disclosed yet.
Beyond the preview
Go deeper on TG ImmunoPharma Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TG ImmunoPharma Co., Ltd..